Laboratory models have been invaluable for the field of microbiology for over 100 years and have provided key insights into core aspects of bacterial physiology such as regulation and metabolism. However, it is important to identify the extent to which these models recapitulate bacterial physiology within a human infection environment. Here, we performed transcriptomics (RNA-seq), focusing on the physiology of the prominent pathogen Staphylococcus aureus in situ in human cystic fibrosis (CF) infection. Through principal-component and hierarchal clustering analyses, we found remarkable conservation in S. aureus gene expression in the CF lung despite differences in the patient clinic, clinical status, age, and therapeutic regimen. We used a machine learning approach to identify an S. aureus transcriptomic signature of 32 genes that can reliably distinguish between S. aureus transcriptomes in the CF lung and in vitro. The majority of these genes were involved in virulence and metabolism and were used to improve a common CF infection model. Collectively, these results advance our knowledge of S. aureus physiology during human CF lung infection and demonstrate how in vitro models can be improved to better capture bacterial physiology in infection. IMPORTANCE Although bacteria have been studied in infection for over 100 years, the majority of these studies have utilized laboratory and animal models that often have unknown relevance to the human infections they are meant to represent. A primary challenge has been to assess bacterial physiology in the human host. To address this challenge, we performed transcriptomics of S. aureus during human cystic fibrosis (CF) lung infection. Using a machine learning framework, we defined a "human CF lung transcriptome signature" that primarily included genes involved in metabolism and virulence. In addition, we were able to apply our findings to improve an in vitro model of CF infection. Understanding bacterial gene expression within human infection is a critical step toward the development of improved laboratory models and new therapeutics.
data are composed of 22 RNA-seq data sets from our and other laboratories (30) (31) (32) during growth under a variety of conditions, including rich complex medium (tryptic soy broth [TSB], lysogeny broth [LB], brain heart infusion broth [BHI] ) and chemically defined medium with either glucose or amino acids as a primary carbon and energy source. In addition, a number of different S. aureus isolates were used in the in vitro studies, including the USA300 community-associated methicillin-resistant strain LAC* (33) , the closely related USA300 strains JE2 (34) and UAMS-1790 (35) , the USA200 strain UAMS-1 (17) , the laboratory strain SH1000 (36) , and the clinical isolate SAU060112 (30) . A complete list of the in vitro samples used in this study is included in Table 2 .
The S. aureus human CF transcriptome is distinct from in vitro models. When assessing gene expression in clinical samples, one concern is biasing the results due to the presence/absence of genes resulting from differences in strain background when making comparisons between conditions. To address this, we constructed a reduced gene set consisting of only 1,960 genes (ϳ70% of the total genes in an S. aureus genome) that are conserved across a set of 15 genetically diverse S. aureus strain backgrounds (see Table S1 in the supplemental material) and mapped transcriptomes to this reduced gene set (9) . In addition, we removed reads mapping to tRNAs and rRNAs from our data sets, since any potential differences in rRNA depletion during library preparation can affect normalization and fold change calculations. A principalcomponent analysis (PCA) based on this resulting data set shows that the human CF sputum samples cluster distinctly from our in vitro models ( Fig. 1A and Fig. S1A ), and they cluster remarkably closely across all 10 patients despite differences in coinfecting microbes, patient status, therapeutic regimen, and geographic location of the clinic. In fact, S. aureus sputum transcriptomes from different patients are more closely associated on the PCA than in vitro samples during different growth phases ( Fig. 1A and Fig. S1A ). In addition to the CF sputum samples, we also included S. aureus transcriptomes from 1 human joint infection (30) and 1 human chronic wound infection in this analysis to determine if S. aureus transcription in human infection in general was similar. We found these samples clustered with the CF sputum samples in our PCA (Fig. S1A ), indicating similarities in gene expression that may be shared across different infection types. Additional principal components (PC) are shown in Fig. S2 as well as a scree plot of the first 20 PCs. We have also included a PCA using only those genes that have reads mapping to them in all of our clinical samples (1,046 common genes) to control for the potential presence/absence of genes in the samples impacting the clustering (Fig. S3 ). We find similar patterns of clustering with this methodology. In addition to principalcomponent analysis, we assessed the similarity of S. aureus gene expression across our sample types with hierarchal clustering (Fig. 1B) . Through this analysis, we found that the human CF sputum samples cluster independently from the in vitro model systems, confirming the PCA results. Interestingly, while we find that the human wound sample clusters with the CF sputum, the human joint infection sample clusters with the in vitro samples by this measure. Expression of virulence factors and metabolic genes differentiate in vivo and in vitro samples. Since the human and in vitro samples clustered independently, we were next interested in determining which functional categories differed between these sample types. We performed differential expression analysis with DESeq2 (37) comparing our in vitro conditions collectively to S. aureus expression in CF sputum to make broad assessments about in vitro versus in vivo growth. We focused on those genes with the largest changes between the two groups to make robust observations (adjusted P value of Ͻ0.05, Ͼ4-fold change [Data Set S1]), and 271 genes were differentially expressed by this measure. To determine functional relationships, genes were annotated with TIGRFAM categories (38) . However, as the TIGRFAM categories did not include virulence factors, annotations for these genes were curated from the literature (6-8, 18, 22, 39-41) . Some of the most differentially expressed genes in humans compared to in vitro were virulence factors, the majority of which had increased expression in CF sputum, and included gamma-hemolysin (hlgABC), superantigen-like proteins (ssl1, ssl2, ssl3, ssl5, ssl9, ssl10, ssl12, ssl13, and ssl14), leukocidins (lukG), extracellular matrix binding proteins (emp, scc, and fnbA), and exopolysaccharide (icaABC). In fact, virulence factors as a category were enriched (Fisher's exact test, adjusted P value of Ͻ0.05) in the differentially expressed genes in CF sputum . For in vitro samples, "CDM glc log" is samples 1 and 2, "CDM glc stat" is samples 3 to 5, "CDM noC log" is samples 6 and 7, "CDM noC stat" is samples 8 and 9, "BHI 1" is samples 10 and 11, "BHI 2" is samples 12 and 13, "LB" is samples 14 to 16, "TSB 1" is samples 17 to 19, and "TSB 2" is samples 20 to 22 listed in Table 2 .
samples compared to in vitro. Normalized read counts for all S. aureus virulence factors conserved across the 15 strain backgrounds are shown in Fig. S4 . In addition to virulence factors, many metabolic genes were differentially expressed in vivo compared to in vitro (adjusted P value of Ͻ0.05, Ͼ2-fold change [Data Set S1]). However, it can be challenging to infer host nutritional levels by comparison to S. aureus transcriptomes from complex conditions with unknown metabolite levels such as those found in rich culture media like BHI, TSB, and LB. Since many of our in vitro data sets were from these rich medium conditions, to better understand the in vivo nutritional environment, we wanted to also compare the human transcriptomes to a well-controlled in vitro condition under which the metabolite levels are known. We decided to compare the CF sputum transcriptomes to exponential growth in chemically defined medium (CDM) with glucose as a primary carbon source. We found that 183 genes were differentially expressed (adjusted P value of Ͻ0.05, Ͼ2-fold change in expression) between these conditions, and a complete list of these genes is included in Data Set S2. Some notable pathways that were differentially expressed are shown in Fig. 2 and include purine biosynthesis, amino acid catabolism, nitrate reduction, and transporters.
When taken together, these two comparisons (human sputum versus all in vitro and human sputum versus CDM glucose) allow us to make general insights into the nutritional status of S. aureus in the CF lung. (i) S. aureus is likely respiring oxygen and not fermenting. S. aureus gene expression under anaerobic conditions has been carefully measured through transcriptomics and proteomics (42) . We find the transcriptomic metabolic profile of S. aureus in the CF lung is nearly opposite that of S. aureus grown anaerobically, with low expression of genes involved in fermentation and acquisition of the alternative electron acceptor nitrate, even compared to aerobic 
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® conditions ( Fig. 2 ; Data Sets S1 and S2). Therefore, it is likely that oxygen is available and is being used by S. aureus. However, oxygen is likely relatively low as the high-affinity cytochrome bd oxidase (cydAB) has increased expression in vivo compared to in vitro growth ( Fig. 2 ; Data Set S3 [these data have been derived and reformatted from Data Sets S1 and S2]). (ii) S. aureus is able to acquire iron in the CF lung, although its concentration is likely low. The biosynthetic pathway for the S. aureus siderophore staphyloferrin B had increased expression in human infection (Data Set S3), indicating that the CF lung is a low-iron environment where S. aureus is likely scavenging Fe 3ϩ . However, there was no change in expression for any of the Fe 2ϩ transporters, and a number of heme uptake genes actually showed reduced expression in the CF lung (43) . (iii) Other key metals such as manganese and zinc are likely limiting in vivo as, in general, transporters for these have increased expression in CF lung infection compared to in vitro ( Fig. 2 ; Data Set S3). Additionally, in vivo, the expression of genes involved in the biosynthesis of the broad-spectrum metallophore staphylopine (44) are also increased.
Identification of a transcriptional signature of S. aureus in human CF infection. One goal of this work was to evaluate the ways in which model systems recapitulate human infection. While basic comparisons between our conditions are insightful, machine learning approaches can be more useful for probing differences between in vitro and human S. aureus transcriptomes. Therefore, we were next interested if we could determine with a machine learning approach a transcriptional signature that could differentiate between S. aureus CF sputum and in vitro transcriptomes. We trained our model with 9 human CF sputum samples from the Emory CF clinic and our 22 in vitro data sets. We used a filter wrapper in the mlr R package to select 50 genes that resulted in the largest information gain (FSelectorRcpp_information.gain) and best differentiated between data types in a support vector machine (SVM) model. We performed both 10-fold cross-validation and leave-one-out cross-validation of the SVM training process and feature selection using our test data set and had 100% accuracy with both methods. This identified 32 features (genes) that were used by the SVM to differentiate human and in vitro S. aureus transcriptomes and were conserved across all iterations of our validation methods (Fig. 3A) . These genes are involved in a variety of functions for S. aureus, including metal acquisition (sirA, sbnI, isdC, isdE, htsA, and cntF), metabolism (uhpT, bshA, htsA, eutD, fbaA, glnA, ptaA, cidC, ldh1, and lctP2), and virulence (hlgC and ssl9). Figure 3A shows the normalized read counts for these genes. A key point is that these are not necessarily all of the important genes that can differentiate between the sample types, nor are they necessarily the most differentially expressed. However, they are effective in discriminating between human CF sputum and in vitro samples when used together. Of note, although some of these genes are coregulated (ldh1 and lctP2; fur, sbnI, and sirA; and isdE and isdC), the performance of this gene set is not reliant on coregulated genes (Table S2) .
Using the SVM model to classify human and in vitro model transcriptomes. In the SVM model, we used only the CF sputum transcriptomes obtained from Emory samples and did not include the human CF sputum sample from Denmark or the human joint and chronic wound infection samples. The rationale was that restriction to these transcriptomes would allow us to test the robustness of our predictive models on human transcriptomes from different clinics and different infection sites. We found the Denmark CF sputum sample was classified correctly as being a transcriptome from human CF sputum (Fig. 3B) using our model. This supports that our model is accurate in classifying S. aureus CF transcriptomes even from different countries and clinics. However, our model appears to be specific to human sputum as it classified the human joint and chronic wound infections as in vitro (Fig. 3B) .
Model systems are often used to study human infections, including those in CF. Over the past decade, our laboratory has developed a synthetic sputum medium (SCFM2) that is meant to mimic the physical and chemical properties of CF sputum (45, 46) . This model has been valuable for studying P. aeruginosa physiology in the CF lung but has not been evaluated in a comprehensive manner for studying S. aureus CF infection.
Therefore, we used our SVM classification scheme to classify S. aureus SCFM2 transcriptomes as human sputum or in vitro. We found that transcriptomes from S. aureus grown in SCFM2 at two growth phases (mid-and late exponential) were classified as in vitro (Fig. 3B) .
As the human samples outside the CF lung and SCFM2 were not classified as human CF sputum by our classification scheme, we were interested in the ways that these transcriptomes "failed" to be classified as CF sputum. It is important to note that the SVM classification scheme utilizes only the 32 genes that were identified as most discriminatory between CF sputum and in vitro transcriptomes. Thus, we next asked which of these 32 genes were not expressed similarly to CF sputum in the human infections outside the CF lung and in SCFM2, with the rationale that this comparison will provide insight into why these transcriptomes were classified as in vitro. To have increased statistical power, we treated the two non-CF human chronic infections as replicates. Figure 3C shows that while some genes in the non-CF human and SCFM2 transcriptomes have similar expression levels as our CF sputum transcriptomes (e.g., isdC, sirA, lctP2, and glnA), many genes involved in metabolism (typA, bshA, htsA, eutD, fbaA, ptaA, cidC, and ldh1) and iron acquisition (isdE and sirA) had a different expression profile than that in the CF sputum and were more similar to in vitro conditions. Additionally, the fold change of a number of genes for S. aureus grown in SCFM2 
® showed the opposite trend from the human sputum samples or was more similar to the in vitro value (Fig. 3C) . A complete gene list containing the results of these comparisons is shown in Data Set S4.
Addition of human neutrophil peptide 1 improves the accuracy of SCFM2. Can we use our gene expression comparisons and SVM approach to improve SCFM2 as a model of S. aureus CF? One of the most striking outcomes of our in vitro-CF sputum comparisons and the SVM was that genes encoding a number of virulence factors were significantly reduced during in vitro growth, including growth in SCFM2. Many of these virulence factors are controlled by the SaeRS system. SaeRS is a two-component regulatory system composed of a membrane-bound histidine kinase and cognate response regulator (47) and has been shown to be activated by components of the innate immune system, particularly neutrophils and a human antimicrobial alphadefensin peptide (16) . Upon infection, the most prominent cell type recruited to the CF lung is neutrophils. As neutrophils produce an alpha-defensin referred to as human neutrophil peptide (HNP-1), we hypothesized that addition of HNP-1 to SCFM2 might induce the SaeRS system and thus improve the ability of the model to mimic S. aureus transcription in CF sputum. To test this hypothesis, we added HNP-1 (16) to SCFM2 at a relevant physiological concentration and grew the samples to mid-exponential phase for transcriptomic analysis. The addition of HNP-1 to SCFM2 increased expression of secreted and surface-associated factors to levels more similar to those in the CF lung, reducing the number of differentially expressed genes in SCFM2 containing HNP-1 versus SCFM2 alone compared to human sputum (Fig. 4) . Genes whose expression became more similar to that in the CF lung included lukGH (encoding a leukocidin), nuc (encoding nuclease), efb (encoding a fibrinogen binding protein), and fnbA (encoding fibronectin binding protein A), which have all been shown to be directly controlled by the SaeRS system (47) (Fig. 4) .
DISCUSSION
It is critical to study the physiology of organisms within their natural environment. However, until recently, studying bacterial pathogens within human infection has been technically prohibitive. Our goal was to expand the S. aureus human transcriptomic data from one sample with high sequencing coverage (30) as well as to provide benchmark data and a framework to assess S. aureus physiology in situ within human infection. To do this, we performed RNA-seq analysis on 10 human CF lung infection samples containing S. aureus and analyzed these samples in the context of 22 in vitro transcriptomes from a variety of conditions. We used RNA-seq data for this study as it is a quantitative, highly robust technique that can be performed with human-derived infection samples. In addition, mRNA levels can be used to infer S. aureus functions from clinical samples, thus providing mechanistic insights into the human growth environment. We found that the S. aureus CF sputum sample transcriptomes were highly similar to one another (Fig. 1) , even more so than the in vitro transcriptomes (see Fig. S1 in the supplemental material), despite differences in clinic location, antibiotic regimen, and comorbidities (Fig. 1 ). This indicates that S. aureus has a definable functional repertoire during CF infection, suggesting that one can make informed a priori assumptions about the physiology of S. aureus in most CF lung infections. We found that many metabolic pathways were differentially expressed in CF sputum than under the in vitro conditions. In general, biosynthetic pathways were reduced in vivo, while transporters and catabolic pathways often had increased expression ( Fig. 2 ; Data Sets S1 and S2). Collectively, this indicates that the CF lung is nutrient rich; therefore, S. aureus does not need to synthesize a number of precursor metabolites. An interesting finding was that genes involved in fermentation were reduced in CF sputum ( Fig. 2 ; Data Set S1). It is generally accepted that S. aureus is pushed toward a fermentative metabolism in vivo in CF sputum, particularly when in the presence of P. aeruginosa (48, 49) . The clinical microbiology of our sputum samples indicates that 8 of these 10 patients harbor P. aeruginosa along with S. aureus in their lungs (Table 1) ; thus, it is intriguing that S. aureus exhibits reduced expression of fermentative pathways in the CF lung compared to monoculture planktonic growth in the lab. These data provide support for the hypothesis that P. aeruginosa and S. aureus do not interact by these in vitro observed mechanisms in the CF lung. One possible explanation is that although both of these species are present in the CF sputum samples, they could be spatially segregated, thus preventing sustained interactions (50) , or that the number of these bacteria, which are not known in these samples, are not sufficient to support an interaction. Regardless, our approach provides benchmark human infection transcriptomic data to begin to approach such questions in complex environments such as CF lung infections.
Using a machine learning approach, we identified a subset of 32 genes that could reliably distinguish between CF sputum transcriptomes and those from in vitro ( Table 3) . While this transcriptomic signature of human CF lung infection could accurately classify a CF sputum sample from another clinic and country (Fig. 3B) , it classified S. aureus transcriptomes from a human joint infection as well as a human chronic wound infection as more likely to be in vitro (Fig. 3B ). The genes that most differentiated the non-CF human infections from those in CF sputum in this transcriptomic signature were involved in metabolism and iron acquisition (Fig. 3C) . These data indicate that S. aureus has a distinct metabolic profile in different human infections, which is important to consider as the metabolic status of bacteria has been shown to impact the efficacy of antibiotics (51) . Additionally, this demonstrates that there are easily distinguished gene expression patterns that can differentiate CF S. aureus lung infections from human infections at other sites. This could be due to the unique infection dynamics of the CF lung, in which microbes colonize the lung where they can evolve for years in the presence of therapeutic treatments. It should be pointed out that while one can discriminate between CF lung and non-CF lung in human infection transcriptomes, expression levels of many genes were highly similar, supporting that there are many S. aureus functional similarities during human infection. Thus, while we can discriminate among S. aureus human infection types using SVM, this does not imply that these conditions do not have functional similarities.
Our results also revealed that our current in vitro models underrepresent the level of virulence factor expression that occurs during human infection, with many virulence factors showing significantly higher expression in vivo than in vitro (Data Set S1). Many of these virulence factors are directly regulated by the SaeRS two-component system regulon (16, 47) , which is known to be responsive to host stimuli such as neutrophils and alpha-defensin (16) . It is likely that the reduced expression of these factors in vitro is therefore due to the absence of an environmental cue. Importantly, we were able to increase the expression of virulence factors in the model system SCFM2 with the addition of an alpha-defensin (HNP-1), improving this model ( Fig. 4 ). Although this led to only a modest improvement in the model, it is important as it indicates that one can target and improve key aspects of in vitro models to better mimic infection using transcriptomics. We focused on improving SCFM2 as it is a model that has been specifically developed to mimic the CF sputum environment. In addition to the supplementation of host molecules, another way one could potentially improve this model is with the use of CF clinical isolates instead of the skin and tissue isolates that comprised the majority of our in vitro samples. Finally, our data indicate that S. aureus is in a fermentative state under many of the in vitro conditions used. S. aureus requires vigorous shaking during in vitro culture to prevent it from entering fermentation; therefore, another possible way to improve these in vitro models is by increasing the aeration, preventing this switch to fermentation. Together, this work highlights the importance of choosing conditions that most closely mimic the aspects of the infection environment to be studied and indicate key areas in which models can be improved.
S. aureus has been studied for over Ͼ135 years (2) , and in that time researchers have developed in vitro models with the goal of understanding S. aureus physiology within infection. While these models have been invaluable, we still do not fully understand how well and in what ways these models mimic the human infection environment. This study contributes to this long line of work as the largest assessment of global S. aureus transcription in human infection. Future research will build on these results and assess the ability of polymicrobial or spatially structured systems to better mimic the in vivo infection environment.
MATERIALS AND METHODS
Strains and culture conditions. The USA300 community-associated methicillin-resistant Staphylococcus aureus strain LAC* (33) was used in this study. Isolates were routinely grown on brain heart infusion agar incubated at 37°C in ambient air. Chemically defined medium (CDM) was prepared as previously described (52) with the following modification for S. aureus: the amino acid and nucleotide stock solution was added at 0.25ϫ to allow the primary carbon source to be exchanged as S. aureus can grow on amino acids. S. aureus was grown in SCFM2 as previously described (24) . Briefly, 750 l of SCFM2 in four-well microchamber slides from Nunc was inoculated at an optical density at 600 nm (OD 600 ) of 0.05 of S. aureus strain LAC*, grown for either 3 or 7 h, and then immediately added to 5 volumes of RNAlater (ThermoFisher). Two technical replicates were combined for each biological replicate. For the addition of HNP-1 to SCFM2, 2.4 M HNP-1 (Sigma-Aldrich) was added to SCFM2 at the time of inoculation and S. aureus was grown in four-well microchambers as described above. After 3 h of growth, samples were immediately added to 5 volumes of RNAlater. Planktonic cultures were grown at 37°C with shaking at 225 rpm and a flask-to-volume ratio of 5:1.
RNA extraction and preparation of sequencing libraries for RNA-seq. In vitro and human samples were prepared as previously described (24) with a few modifications for the human samples. For the human sputum samples, expectorated sputum was collected from adult patients who were clinically stable, immediately added to RNAlater, and stored at 4°C overnight and then at Ϫ80°C. Samples in RNAlater were thawed on ice and centrifuged at 4°C for 30 min at 10,000 ϫ g. RNAlater was removed from the sample, and sputum was transferred to bead-beating tubes containing a mixture of large and small beads (2-mm zirconia and 0.1-mm zirconia-silica, respectively). In vitro cultures stored in RNAlater were pelleted, resuspended in 1 ml RNA-Bee, and transferred to bead-beating tubes. Samples were resuspended in RNase-and DNase-free TE buffer (Acros Organics), and lysozyme (1-mg/ml final concentration) and lysostaphin (0.17-mg/ml final concentration) were added to each sample. Samples were incubated at 37°C for 30 min to enzymatically lyse cells. RNA-Bee was added to each sample, and samples were lysed mechanically by bead beating three times for 30 s, placing the tubes on ice for Ն1 min between each homogenization. Amounts of 200 l of chloroform per 1 ml of RNA-Bee were added, and the tubes were shaken vigorously for 30 s and incubated on ice for 5 min or overnight to allow phases to partition. Samples were centrifuged at 12,000 ϫ g for 15 min at 4°C to separate the aqueous and organic phases. The aqueous phase from each tube was transferred to a new microcentrifuge tube to which 0.5 ml isopropanol per 1 ml of RNA-Bee was added in addition to 20 g of linear acrylamide, and the tubes were incubated at Ϫ80°C overnight. Samples were thawed on ice and centrifuged at 12,000 ϫ g for 30 min at 4°C. Pellets were washed with 1 ml 75% ethanol, air dried for 5 min, and resuspended in 100 l of RNase-free water. The RNA concentration for each sample was determined with a NanoDrop spectrophotometer (Thermo Fisher Scientific). rRNA was depleted using the RiboZero Gold bacterial kit (Illumina) for the in vitro samples and the RiboZero Gold epidemiology kit (Illumina) for the human samples and purified by ethanol precipitation using linear acrylamide to help precipitate the RNA. The depleted RNA was fragmented for 2 min with the NEBNext Magnesium RNA fragmentation module kit, and cDNA libraries were prepared using the NEBNext Multiplex small RNA library prep kit (New England Biolabs) per the manufacturer's instructions. Libraries were sequenced at the Molecular Evolution Core at the Georgia Institute of Technology by Illumina NextSeq500 75-bp single-end runs.
Bioinformatic analysis of RNA-seq data. RNA-seq reads were trimmed using Cutadapt 1.18 with a minimum read length threshold of 18 bases (53) . Reads were mapped to a pangenome and collapsed onto orthologs in the S. aureus reference strain genome USA300_FPR3757 (accession number GCF_000013465.1) downloaded from the National Center for Biotechnology Information using Bowtie 2.3.2 with the default parameters for end-to-end alignment (54) . Reads were tallied and assigned to only those genes common to all strains in the S. aureus 15-strain pangenome (1,960 genes [see Table S1 in the supplemental material) using the htseq-count function in the HTSeq package (55) (v. 0.11.2-0). Reads mapping to rRNAs and tRNAs were removed from the analysis. The remaining raw reads were normalized using the estimateSizeFactors() function and transformed using the varianceStabilizingTransformation() function in the DESeq2 package prior to analysis. Principal components were determined using the prcomp() function. In addition to this methodology, we also performed this analysis using a subset of genes where all human samples had at least 1 read in all of the genes used, leading to a common set of 1,046 genes. Principal components were determined in the same way as described above. Differential expression was determined with DESeq2 (37) with betaPrior set to true. The hierarchal clustering was performed in the heatmap3 R package (56) . Heatmaps were generated from varianceStabilizing-Transformation normalized read counts using Prism 7 (GraphPad). For the machine learning component of the paper, the R package mlr was used (57) . Feature selection and validation were performed using a wrapper and the "FSelectorRccp_information.gain" filter to select 50 features, and this was combined with 10-fold cross-validation and leave-one-out cross-validation methods. We chose 32 features that were used in all iterations of cross-validation to build and train the SVM model. Ethical statement. Expectorated CF sputum samples for this study were collected from Emory ϩ Children's Center for Cystic Fibrosis and Airways Disease Research as previously described by our group (24) with IRB approval (Georgia Tech approval no. H18220).
